Core Insights - Eli Lilly's GLP-1 weight-loss drug has shown potential in temporarily suppressing food-craving signals in patients with severe binge-eating issues [1] Group 1 - Researchers have been monitoring brain activity in a patient with severe binge-eating problems [1] - The findings suggest that the drug may have a significant impact on reducing food cravings [1]

Core Insights - Eli Lilly reported adjusted earnings of $7.02 per share on $17.6 billion in third-quarter sales, exceeding analyst expectations of $5.89 per share and $16.05 billion in sales [1][2] - The company experienced significant growth in sales for its diabetes treatment Mounjaro, which generated $6.52 billion, and Zepbound, a weight-loss drug, which brought in $3.59 billion, both surpassing analyst projections [2] - Eli Lilly raised its full-year guidance, now expecting adjusted earnings of $23-$23.70 per share on sales of $63 billion-$63.5 billion, compared to the Street's expectations of $22.48 earnings per share and $61.74 billion in sales [2] Stock Performance - Eli Lilly's stock rose 3.9% to 845 in premarket trading, with a short-term high of 864.35 identified as a potential entry point for investors [3] - The stock is currently trading above key moving averages, although it has a low IBD Digital Relative Strength Rating of 33, indicating it ranks in the bottom third of stocks based on 12-month performance [3]